Anavex Life Sciences Corp (AVXL)

[polarbear77]

I believe you’re correct xena; at least at prices possibly offered thus far.

When our future hinges largely on efficacy (safety having been established), and after reviewing the numerous positive signs/signals/insider buying/new large stock option grants/articles/presentations/words from outside experts/validations from independent labs/abstracts (not the least of which the soon-to-be-published Journal of the Alzheimer’s Association article below), it wouldn’t surprise me if Dr M and our BOD are now simply interested in pressing forward on their own through these next precision medicine 21st CCA trials.

Especially in light of the fact that Dr M has indicated that they’ve financing in place for at least 2 more years with no debt.

They likely could’ve sold out on the cheap long ago. Why wouldn’t they?

Might they have significant reason for optimism following study after study after study after study after study of positive and encouraging efficacious results in this CNS disease space with significant unmet needs?

Might it be because the bar is so low in terms of exceeding the safety & efficacy of current SOC drugs?

Might it be because they’ve already had in-depth precision medicine trial design discussions with regulators and possibly have confidence in meeting several other quality of life endpoints such as depression or insomnia (sleep is crucial in helping to reduce oxidative stress and inflammation per recent articles and Dr Perry; and reducing inflammation seems a common important thread among CNS indications, does it not?)?

Might it be that our BOD is aware of the body of previously published peer-reviewed papers showing the positive effects of Sigma-1 receptor agonists and “a2-73 has seen specific preclinical validation in 10 different neurodegenerative diseases” (credit Nobrainerstocks sticky post)?

They’ve been analyzing and poring over “what we have” for months/years now. If our approach and MOA and potential for success was looking weak, then I’ve a tough time envisioning:

• the BOD granting huge new option grants a month ago to the ceo and cfo
• the ceo moving forward into confirmatory trials (which they’re clearly planning to do) without a high confidence level in their ultimate success (he has intomated this mentality before)
• telling all of us in May 2017 that they’ve a considerable number of regulatory filings planned
• that Ariana would’ve told us approximately 20 times in their recent presentation that they’d found a strong dose/blood concentration level response correlation in our ph2a AD participants despite non optimized dosing

Plenty of positives here, still struggling to find the negatives (aside from some FRUSTRATING delays and a seemingly ABSURD market cap).

http://www.alzheimersanddementia.com/article/S1552-5260(17)33851-7/fulltext

DYODD and success is by no means guaranteed. Go Anavex